Certara launches Cardiac Safety Simulator to determine arrhythmia risk for drug candidates

Based on an in-silico model of human ventricular heart cells, Certara’s Cardiac Safety Simulator (CSS) helps sponsors to assess arrhythmia risk before a new drug candidate enters clinical trials and determine safe drug doses for specific patient populations.


Certara
 
Based on an in-silicomodel of human ventricular heart cells, Certara's Cardiac Safety Simulator(CSS) helps sponsors to assess arrhythmia risk before a new drug candidateenters clinical trials and determine safe drug doses for specific patientpopulations.
 
Certara
 


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022